Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab + prednisone
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This combination therapy consists of adalimumab, a fully human monoclonal antibody, and prednisone, a synthetic corticosteroid. Adalimumab functions by specifically binding to tumor necrosis factor-alpha (TNF-α) and neutralizing its biological function, thereby reducing the inflammatory cascade characteristic of autoimmune diseases. Prednisone acts as a glucocorticoid receptor agonist, exerting broad anti-inflammatory and immunosuppressive effects. This specific regimen is being evaluated by the Fondazione IRCCS Policlinico San Matteo di Pavia in the Phase IV CURE (Adalimumab in Early Rheumatoid Arthritis) clinical trial. The study investigates the efficacy of intensive early treatment using adalimumab combined with methotrexate and high-dose prednisone to induce and maintain remission in patients with early-stage rheumatoid arthritis.
- Other names
- adalimumab + prednisone + methotrexateCURE trial regimen
02
Targets
GR (Glucocorticoid receptor)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on adalimumab + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab + prednisone.